
7-Year Data Show Feasibility of Elective Treatment Interruption of Venetoclax/Ibrutinib in R/R MCL
Treatment with venetoclax (Venclexta) plus ibrutinib (Imbruvica) demonstrated long-term durable responses with acceptable toxicity in patients with relapsed/refractory mantle cell lymphoma (MCL), and maintained disease control following elective …